Market Overview

UPDATE: Jefferies Initiates Coverage on CVS Caremark on Position to Benefit from Multiple Catalysts

Share:
Related CVS
AcelRx: Replacing Morphine With Department Of Defense Funding
Headline Risk Haunts PBMs As Drug Pricing Debate Intensifies
Numeric Investors Llc Buys Gilead Sciences, Microsoft, Apple, Sells Facebook, Symantec, Comcast (GuruFocus)

In a report published Tuesday, Jefferies analyst Mark Wiltamuth initiated coverage on CVS Caremark Corporation (NYSE: CVS) with a Buy rating and $71.00 price target.

In the report, Jefferies noted, “We recommend CVS Caremark as a core holding as we view it as the drug retailer best positioned to benefit from the Affordable Care Act, the aging of baby boomers and double-digit growth in specialty pharmacy. As the #1 US drugstore, #2 PBM, #2 in Medicare Part D insurance plans, and #2 in Specialty Pharmacy, the company's integrated PBM/retail model is best positioned to capture the coming shifts in the marketplace, in our view.”

CVS Caremark Corporation closed on Monday at $56.73.

Latest Ratings for CVS

DateFirmActionFromTo
Feb 2017BairdDowngradesOutperformNeutral
Dec 2016JefferiesAssumesBuyHold
Oct 2016UBSInitiates Coverage onBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Jefferies Mark WiltamuthAnalyst Color Initiation Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!